The Diagnostic Imaging CT modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of CT across the healthcare continuum, from various cancer screenings, such as lung and colon, to cardiothoracic imaging, to appendicitis, and more.
April 3rd 2025
After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment
April 4, 2025 | New York, NY & Virtual
Register Now!
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
43rd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 12-14, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies
View More
Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
View More
CMS Suspends IDR Process of No Surprises Act After Federal Court Vacates IDR Fee Increase
August 7th 2023The controversial Independent Dispute Resolution (IDR) process of the No Surprises Act was temporarily suspended by the CMS on August 4 due to a federal court ruling that vacated a substantial administrative fee increase and batching rule from the CMS that reportedly curtailed challenges of claim reimbursement by radiologists and other providers.
Emerging Concepts with ICM Reduction and Photon Counting for Coronary CT Angiography
August 2nd 2023Emerging research suggests that achieving an optimal virtual monoenergetic image (VMI) energy level with photon-counting computed tomography (CT) may allow up to a 40 percent reduction of contrast media dosing for coronary CT angiography.
Study: AI Assessment of Chest CT May Predict Multiple Mortality Risks
July 26th 2023In a study of over 20,700 people, researchers found that artificial intelligence (AI) analysis of body composition measurements via lung cancer screening computed tomography (CT) exams improves the prediction of mortality risks for lung cancer, cardiovascular disease, and all-cause mortality.
How Socioeconomic Disparities Affect Follow-Up of Incidental Pulmonary Nodules on CT
July 21st 2023In a study of nearly 2,500 patients with incidental pulmonary nodules (IPN) on chest computed tomography (CT) exams, 69.5 percent of those in the highest quartile of the CDC’s Social Vulnerability Index (SVI) had inappropriate IPN follow-up in comparison to 54.3 percent of those in the lowest quartile of the CDC SVI.